Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Investing Activities (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Cash from Investing Activities readings, the most recent being $5.9 million for Q1 2026.

  • Quarterly Cash from Investing Activities rose 16.62% to $5.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$49.0 million through Mar 2026, down 224.04% year-over-year, with the annual reading at -$49.9 million for FY2025, 191.32% down from the prior year.
  • Cash from Investing Activities hit $5.9 million in Q1 2026 for Ovid Therapeutics, up from -$72.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $30.2 million in Q1 2023 and bottomed at -$80.7 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is -$4.7 million, with a median of $5.1 million recorded in 2025.
  • The largest annual shift saw Cash from Investing Activities plummeted 9246.58% in 2022 before it surged 2908.96% in 2023.
  • Ovid Therapeutics' Cash from Investing Activities stood at -$4.2 million in 2022, then tumbled by 1063.59% to -$48.5 million in 2023, then surged by 143.89% to $21.3 million in 2024, then crashed by 438.45% to -$72.1 million in 2025, then soared by 108.26% to $5.9 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Cash from Investing Activities are $5.9 million (Q1 2026), -$72.1 million (Q4 2025), and $5.1 million (Q3 2025).